Sorlozano-Puerto, AntonioNavarro-Mari, Jose MariaGutierrez-Fernandez, Jose2023-01-252023-01-252017-01-24Sorlózano-Puerto A, Navarro-Marí JM, Gutiérrez-Fernández J. Activity of Fosfomycin on Clinical Isolates of Campylobacter jejuni and Campylobacter coli of Enteric Origin. Antimicrob Agents Chemother. 2017 Jan 24;61(2):e02317-16.http://hdl.handle.net/10668/10803We read with interest the report by Aguilar-Company et al. (1) on two cases of recurrent enteritis due to Campylobacter coli successfully treated with oral fosfomycin-tromethamine. Campylobacter spp. are among the main microorganisms responsible for enteritis and are the principal cause of bacterial diarrhea in our setting, ahead of the genus Salmonella; they are responsible for 44.0% of cases, a percentage that has substantially increased over recent years (2). Although the disease is often mild and self-limiting, it is frequently observed in patients with immunologic alterations and there is growing resistance to macrolides and fluoroquinolones, increasing the risk of a lethal outcome (3).enAnimalsChickensFosfomycinCampylobacter InfectionsCampylobacter jejuniCampylobacter coliMacrolidesAnti-Bacterial AgentsBacterial InfectionsDiarrhealetter to the editor28119317Restricted AccessEnteritisDiarreaMacrólidosSalmonellaEgoPacientesCampylobacter coliFluoroquinolonasFosfomicina10.1128/AAC.02317-161098-6596PMC5278721https://europepmc.org/articles/pmc5278721?pdf=renderhttps://www.ncbi.nlm.nih.gov/pmc/articles/PMC5278721/pdf